Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 35.33% is in line with its 5-year average of 33.41%, around the middle of its 5-year range (26.68%–50.15%).
2.68% above its 12-month average of 34.41%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 26.74%.
NET PROFIT MARGIN
35.33%
NET PROFIT MARGIN AVG TTM
34.41%
NET PROFIT MARGIN AVG 3Y
33.84%
NET PROFIT MARGIN AVG 5Y
33.41%
NET PROFIT MARGIN AVG 10Y
33.58%
NET PROFIT MARGIN AVG 15Y
32.26%
NET PROFIT MARGIN AVG 20Y
29.76%
CURRENT VS TTM AVG
+2.68%
CURRENT VS 3Y AVG
+4.41%
CURRENT VS 5Y AVG
+5.74%
CURRENT VS 10Y AVG
+5.20%
CURRENT VS 15Y AVG
+9.53%
CURRENT VS 20Y AVG
+18.71%
SECTOR MEDIAN · HEALTHCARE
9.21%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+283.81%
vs the sector median at left
Novo Nordisk A/S
Market Cap
$188.86B
Net Profit Margin
35.33%
TTM Avg
34.41%
3Y Avg
33.84%
5Y Avg
33.41%
Market Cap
$181.64B
Net Profit Margin
-10.64%
TTM Avg
15.29%
3Y Avg
17.07%
5Y Avg
15.27%
Market Cap
$176.59B
Net Profit Margin
11.65%
TTM Avg
23.34%
3Y Avg
19.20%
5Y Avg
17.71%
Market Cap
$147.13B
Net Profit Margin
15.95%
TTM Avg
15.52%
3Y Avg
19.51%
5Y Avg
19.37%
Market Cap
$238.35B
Net Profit Margin
15.06%
TTM Avg
14.95%
3Y Avg
14.84%
5Y Avg
16.47%
Market Cap
$133.24B
Net Profit Margin
28.45%
TTM Avg
28.09%
3Y Avg
25.67%
5Y Avg
26.14%
Market Cap
$130.62B
Net Profit Margin
34.89%
TTM Avg
13.94%
3Y Avg
25.44%
5Y Avg
29.40%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $188.86B | 35.33% | 34.41% | 33.84% | 33.41% |
| Gilead Sciences, Inc. (GILD)vs › | $181.64B | -10.64% | 15.29% | 17.07% | 15.27% |
| Abbott Laboratories (ABT)vs › | $176.59B | 11.65% | 23.34% | 19.20% | 17.71% |
| Amgen Inc. (AMGN)vs › | $202.74B | 22.93% | 16.61% | 20.49% | 22.20% |
| Pfizer Inc. (PFE)vs › | $157.02B | 6.81% | 12.51% | 14.97% | 18.18% |
| Danaher Corporation (DHR)vs › | $147.13B | 15.95% | 15.52% | 19.51% | 19.37% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $238.35B | 15.06% | 14.95% | 14.84% | 16.47% |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.24B | 28.45% | 28.09% | 25.67% | 26.14% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.62B | 34.89% | 13.94% | 25.44% | 29.40% |
| Bristol-Myers Squibb Company (BMY)vs › | $130.18B | 18.87% | -1.95% | 6.91% | 3.60% |
Operating Margin
43.1%
Net Profit Margin
35.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 26.74% |
| 2026-03-31 | 50.15% |
| 2025-12-31 | 33.98% |
| 2025-09-30 | 26.68% |
| 2025-06-30 | 34.48% |
| 2025-03-31 | 37.18% |
| 2024-12-31 | 32.95% |
| 2024-09-30 | 38.28% |
| 2024-06-30 | 29.46% |
| 2024-03-31 | 38.88% |
| 2023-12-31 | 33.35% |
| 2023-09-30 | 38.27% |
| 2023-06-30 | 35.78% |
| 2023-03-31 | 37.13% |
| 2022-12-31 | 28.26% |
| 2022-09-30 | 31.61% |
| 2022-06-30 | 32.27% |
| 2022-03-31 | 33.81% |
| 2021-12-31 | 28.41% |
| 2021-09-30 | 34.02% |
| 2021-06-30 | 36.69% |
| 2021-03-31 | 37.34% |
| 2020-12-31 | 28.99% |
| 2020-09-30 | 33.30% |
| 2020-06-30 | 35.41% |
| 2020-03-31 | 35.12% |
| 2019-12-31 | 26.89% |
| 2019-09-30 | 33.67% |
| 2019-06-30 | 31.94% |
| 2019-03-31 | 35.66% |
| 2018-12-31 | 28.58% |
| 2018-09-30 | 32.55% |
| 2018-06-30 | 37.74% |
| 2018-03-31 | 39.92% |
| 2017-12-31 | 29.48% |
| 2017-09-30 | 36.71% |
| 2017-06-30 | 34.75% |
| 2017-03-31 | 35.70% |
| 2016-12-31 | 29.42% |
| 2016-09-30 | 35.60% |
| 2016-06-30 | 36.30% |
| 2016-03-31 | 34.75% |
| 2015-12-31 | 28.60% |
| 2015-09-30 | 31.29% |
| 2015-06-30 | 30.83% |
| 2015-03-31 | 39.19% |
| 2014-12-31 | 26.56% |
| 2014-09-30 | 29.21% |
| 2014-06-30 | 32.34% |
| 2014-03-31 | 31.75% |
| 2013-12-31 | 27.90% |
| 2013-09-30 | 31.28% |
| 2013-06-30 | 31.50% |
| 2013-03-31 | 29.94% |
| 2012-12-31 | 27.45% |
| 2012-09-30 | 28.56% |
| 2012-06-30 | 27.46% |
| 2012-03-31 | 26.27% |
| 2011-12-31 | 25.88% |
| 2011-09-30 | 25.41% |
| 2011-06-30 | 25.84% |
| 2011-03-31 | 25.95% |
| 2010-12-31 | 24.47% |
| 2010-09-30 | 23.00% |
| 2010-06-30 | 23.05% |
| 2010-03-31 | 24.31% |
| 2009-12-31 | 17.78% |
| 2009-09-30 | 22.01% |
| 2009-06-30 | 23.01% |
| 2009-03-31 | 21.60% |
| 2008-12-31 | 18.54% |
| 2008-09-30 | 23.69% |
| 2008-06-30 | 22.26% |
| 2008-03-31 | 20.54% |
| 2007-12-31 | 9.02% |
| 2007-09-30 | 20.80% |
| 2007-06-30 | 34.57% |
| 2007-03-31 | 17.40% |
| 2006-12-31 | 16.44% |
| 2006-09-30 | 18.53% |
| 2006-06-30 | 17.94% |
| 2006-03-31 | 13.55% |
| 2005-12-31 | 12.68% |
| 2005-09-30 | 19.90% |
| 2005-06-30 | 20.31% |
| 2005-03-31 | 16.93% |
| 2004-12-31 | 18.00% |
| 2004-09-30 | 16.59% |
| 2004-06-30 | 17.77% |
| 2004-03-31 | 16.39% |
| 2003-12-31 | 18.78% |
| 2003-09-30 | 16.89% |
| 2003-06-30 | 19.72% |
| 2003-03-31 | 17.86% |
| 2002-12-31 | 17.44% |
| 2002-09-30 | 15.52% |
